Arixa Pharmaceuticals, Inc.
http://www.arixapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arixa Pharmaceuticals, Inc.
Big Pharma Must Diversify To Tackle Antimicrobial Resistance
Big pharma must bet on biotech if the industry is to tackle the looming issue of superbugs, argues the Access To Medicine Foundation.
Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned
UK-listed Arix completed its first Venture Investment in Public Equity (VIPE), leading a A$24m (£13.4m) investment in Australian biotech Pharmaxis.
Venture Funding Deals: Two Companies With China Ties Raise $260m Each
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice